Tag: Zynlonta
European Commission Grants Orphan Drug Designation to Loncastuximab Tesirine
The European Commission has granted Orphan Drug Designation to loncastuximab tesirine (Zynlonta®; ADC Therapeutics); previously known as ADCT-402, a CD19-targeted ADC, for the treatment...
Results of LOTIS-2 Study of Loncastuximab Tesirine Shows Substantial Single-agent Activity,...
Results of LOTIS-2, a multicenter, open-label, single-arm Phase II clinical trial evaluating the safety and efficacy of single-agent loncastuximab tesirine-lpyl (Zynlonta™; ADC Therapeutics; previously...
Withdrawal of FDA’s Accelerate Approved Therapeutic Agents may harm Patients
The United States Food and Drug Administration’s (FDA) program to accelerate approval of some promising therapeutic agents has recently come under fire due to...
Sterling Pharma Solutions Acquires ADC Biotechnology
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology, a UK-based bioconjugation development services business specializing...
FDA Approves Loncastuximab Tesirine in Treatment of Relapsed or Refractory Diffuse...
Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common form of blood cancer. Lymphomas occur when cells of the...
